OrbusNeich Unveils Data On Genous Bio-engineered R Stent
The presentations delivered by Robbert de Winter of the Academic Medical Center (AMC) in Amsterdam, and Wojciech Wojakowski from Medical University of Silesia in Poland, focused on the
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.